Introduction {#S1}
============

It is now clear that the tumor microenvironment (TME) is essential in tumorigenesis ([@B88]). Different immune players are found in the TME, such as those pertaining to innate immunity \[i.e., macrophages, neutrophils, mast cells, myeloid-derived suppressor cells (MSDCs), dendritic cells (DCs), and natural killer (NK) cells\] and those of adaptive immunity (T and B lymphocytes) ([@B132]). Immune cells within the TME give rise to an inflammatory response, which plays a fundamental role in all stages of tumor growth ([@B88]), where on one hand it can stimulate an anti-tumor immune reaction (immunosurveillance), and on the other hand it can be exploited to promote cancer progression (immunoediting) ([@B98]). In addition, the TME is also composed of tumor stroma cells that have multifaceted interactions with immune cells \[mesenchymal stromal cells (MSCs), fibroblasts, endothelial cells, and pericytes\] ([@B33]). The heterotypic interactions that occur between these different players are highly complex and involve the exchange of molecules such as cytokines, chemokines, and mitogens, which are crucial in determining a pro- or anti-tumor outcome.

MSCs isolated from bone marrow, adipose tissue, and fetal tissues are also intensely explored as therapeutic interventions in various inflammatory-based disorders, including cancer. The rationale behind their use lies within their remarkable migration ability, which can be employed for therapeutic strategies, such as the delivery and local secretion of bioactive factors and/or for the tumor-specific delivery of chemotherapeutic agents. The challenges that lie ahead of the transition from bench to bedside involve a superior understanding of the interplay between the tumor, its microenvironment, and administered/exogenous MSC. Indeed, once caught in the tumor net, MSCs can be hijacked by the malignant cells and manipulated for the tumor's own advantage. Nonetheless, many studies have also ascertained that exogenous MSCs restrain tumor progression.

In this review, we will discuss MSCs in the context of the TME and more specifically immune cells, and the interactions between MSCs and immune cells within the TME that can either inhibit or favor tumor growth. We also discuss how MSCs can be used as a therapeutic strategy in cancer, with a particular focus on perinatal MSCs, the latter of which has been our research interest for over 15 years.

The Immune System in Cancer {#S2}
===========================

Tumor Suppression: Immunosurveillance {#S2.SS1}
-------------------------------------

The importance of immune cells (and inflammation) in controlling and contributing to tumor progression has been acknowledged for decades. Both innate and adaptive immune components actively patrol the body to identify and eradicate incipient tumor cells, and the description of tumor-infiltrating lymphocytes with effector and memory functions within primary tumors and their metastases have been largely described ([@B96]). The presence of an immune infiltrate is generally associated to good prognosis; however, this is largely dependent on the tumor type, location of the cells, and their state of activation ([@B9]). Tumor cells express mutated neo-antigens, non-mutated antigens encoded by genes overexpressed by cancer cells, or antigens encoded by differentiation genes related to the cancer's tissue of origin. DCs process tumor antigens and promote their presentation to T cells, generating an anti-tumor response. Within T cells, CD8^+^ cytotoxic T cells remain the most potent mediators of anti-tumor immunity, and a response directed by either CD4^+^ T helper 1 (Th1) cells or Th17 cells promote CD8^+^ effector T cell responses ([@B90]). Their efficacy is suggested by the fact that a large infiltration of CD8^+^ cytotoxic T cells is linked to a favorable prognosis in different types of tumors, such as breast, ovarian, lung, and colorectal cancer ([@B9]).

Several studies have underlined the critical and distinct roles for γδ T cells, and αβ T cells ([@B55]), as well as NK and NKT cells, in immunosurveillance against cancer ([@B123]; [@B43]) in which interferon-γ (IFN-γ), perforin, and IFN-α/β represent key factors involved in triggering cancer cell death ([@B123]; [@B43]). B lymphocytes can also promote anti-tumor immunity, as shown by the detection of antibodies against tumor antigens in the serum of cancer patients ([@B142]). Antibodies have multifaceted functions in the TME. They can activate the complement cascade, alter the function of their targets on cancer cells, opsonize tumor cells for antigen presentation by DC, or contribute to NK cell-mediated tumor killing via antibody-dependent cell-mediated cytotoxicity ([@B142]). Classically, T-cell priming occurs in tumor-draining secondary lymph nodes; however, spontaneously organized tertiary lymphoid organ structures can be encountered in tumors, suggesting a local anti-tumor defense, with a T-cell education that can occur within the tumor stroma, thus suggesting a local T-cell education and anti-tumor defense. Again, their presence is associated with favorable prognosis in most solid malignancies ([@B2]; [@B117]).

Tumor Promotion: Immunoediting {#S2.SS2}
------------------------------

The surveillance of immune cells seems to be achieved only at the earliest stages of tumorigenesis. In the majority of established tumors, the presence of lymphocytes is not sufficient for curbing tumor growth. In addition, whereas controlled inflammation may be involved in the eradication of tumors, excessive inflammation may facilitate the transformation process. These considerations have given rise to the concept referred to as immunoediting ([@B43]) whereby tumor cells constantly edit and modulate the host antitumor immune response, thus shaping tumor immunogenicity and clonal selection and ultimately shifting the balance in favor of tumor growth. Furthermore, in the initial phases of tumor expansion and progression, tumor cells contribute to creating an inflammatory milieu ([@B30]) by producing and releasing high amount of molecules that either directly or indirectly induce cell proliferation, recruit inflammatory cells that further support tumor growth ([@B113]; [@B57]), and increase production of reactive oxygen species ([@B30]; [@B75]).

However, within the TME, there are different cells, such as MSCs, that can impact the immune response ([Figure 1](#F1){ref-type="fig"}), the latter of which has a profound impact on tumor progression.

![The role of MSC in the tumor microenvironment. Mutations occurring in cells can trigger tumor initiation. During the initial steps, tumor cells proliferate, produce, and release antigens that can be recognized by the immune system. At this point, a subtle balance between the action of immunosurveillance performed by both innate and adaptive immunity counteracts the actions of tumor cells giving rise to a complex network of interactions within the surrounding tumor microenvironment (TME). Indeed, MSCs in contact with the tumor cells, referred to as tumor-associated MSC (TA-MSC), could be considered a crucial axis of these interactions by altering tumor cell phenotype and the release of cytokines and other molecules that can in turn trigger the education of immune cells and of other progenitor cells present in the TME. These interactions give rise to MSC involvement in immunosurveillance **(A)** or immune-editing **(B)**, whereby MSCs can stimulate an anti-tumor immune reaction or skew immune cells toward an immune suppressive phenotype thus favoring immune evasion. T eff, T effector; DC, dendritic cells; Treg, T regulatory cell; MDSC, myeloid derived suppressor cell; MSC, mesenchymal stromal cell; TA-MSC, tumor associated MSC; M1, macrophage type M1; TAM, tumor associated macrophage.](fcell-08-00447-g001){#F1}

MSCs in the TME {#S3}
===============

Regardless of the biological setting, MSCs perform supportive and regenerative functions, thus nourishing the surrounding environment, and MSCs located in the same tissue but exposed to different stimuli may adjust their behavior accordingly, as demonstrated by three-dimensional models that study the interactions between MSCs, tumor cells, and immune cells ([@B106]). Indeed, stromal cell heterogeneity has been attributed to stage of development, tissue of origin, and tissue microenvironment ([@B82]).

Generally, MSCs constitute an important component of the tumor stroma (herein referred to as tumor-associated MSC, TA-MSC). Faithful to their intrinsic role as supportive cells ([@B19]), MSCs have been shown to act in a multi-modal fashion and to directly or indirectly contribute to tumor survival and progression, although evolving data also argue for a role in tumor regression ([@B99]).

Before digging into MSC functions within the TME, it is important to clearly define MSCs, their origin, and what attracts them to malignancy; in the following sections, we will discuss these aspects.

MSC Phenotype and Origin {#S3.SS1}
------------------------

MSCs are primordial multi-potent fibroblast-like cells first described in the bone marrow by [@B50], [@B49], with the capacity to regenerate bone marrow stroma at heterotypic sites ([@B115]). These cells are now believed to reside in almost all fetal and post-natal organs ([@B32]; [@B31]; [@B89]), bearing tissue-specific transcriptional profiles and lineage capabilities ([@B116]).

Owing to the lack of unequivocal markers of endogenous MSC, our knowledge of the properties of these cells has its roots in *in vitro* studies. Indeed, the difficulties encountered in discriminating naïve MSCs from other cell populations *in vivo*, such as fibroblasts ([@B124]) and pericytes ([@B18]), persist also in cancer. As a matter of fact, cancer-associated fibroblasts (CAFs) coexist as heterogeneous population comprising cells with overlapping phenotypes, whose proportion may vary according to the tumor, and of which MSCs constitute only a fraction, thus often generating inconsistency and confusion within the field.

As bone marrow-derived cells constitute the earliest and the best characterized MSC (BM-MSC), most of the studies exploited their phenotypic pattern to isolate mesenchymal stromal-like cells from various sources, including cancer. In 2006, a position paper by the International Society for Cellular Therapy (ISCT) ([@B38]) delineated a set of minimal criteria to identify human BM-MSC *in vitro*, such as (a) plastic adherence; (b) positive expression of CD105, CD73, and CD90, and absence of the hematopoietic antigens CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR; and (c) multi-lineage differentiation. The BM-MSC phenotype has often been used as a reference for the TA-MSC phenotype.

MSCs have been isolated from different types of human malignancies, including head and neck ([@B66]), glioma ([@B10]; [@B60]; [@B118]; [@B130]), breast metastasis ([@B56]), cervical ([@B6]), ovarian ([@B92]; [@B29]; [@B97]), lung ([@B51]), prostate ([@B61]), neuroblastoma ([@B104]), and colorectal ([@B144]) cancer. Even if the MSCs in these studies adhered to the ISCT phenotype ([@B38]), it is important to bear in mind that tumor cells can also exhibit a mesenchymal-like phenotype, making it difficult, or even impossible, to discriminate them from MSCs.

MSCs have often divided the scientific community concerning many aspects of their biology. In cancer, one of the questions that is still a matter of debate is whether TA-MSCs originate from the local microenvironment or are recruited from remote locations of the body. Several studies have indeed shown that CAFs may arise from local fibroblasts and MSCs ([@B133]; [@B45]; [@B74]; [@B119]; [@B4]), from adipocytes and adipocyte-associated stromal cells ([@B146], [@B147]; [@B34]; [@B14]), from the recruitment of BM-MSCs into the tumor tissue ([@B35], [@B36]; [@B94]; [@B125]; [@B107]; [@B71]; [@B65]; [@B17]; [@B111]; [@B11]), from endothelial-to-mesenchymal transition (EndMT) of tumor-associated endothelial cells ([@B143]), and from epithelial-to-mesenchymal transition (EMT) of non-malignant or malignant epithelial cells ([@B109]). Several pathways have been reported to drive the transition of MSCs into CAFs, such as epigenomic reprogramming via lactate in pancreatic cancer ([@B11]), exposure to oxidative stress in breast cancer ([@B131]), C-X-C chemokine receptor type 6 (CXCR6) ([@B64]), and transforming growth factor (TGF)β1 ([@B8]) signaling in prostate cancer, and a supportive role for CD44 in preserving a functional phenotype of CAF has been described ([@B126]). Once within the tumor, BM-MSCs become activated fibroblasts, express markers typical of myofibroblasts such as alpha smooth muscle actin (α-SMA), vimentin, or fibroblast specific protein (FSP) ([@B107]) and contribute to extracellular matrix remodeling ([@B42]), eventually fine-tuning their activation state according to the clues they perceive ([@B5]). Activated fibroblasts further display enhanced proliferative and migratory capacity as a consequence of TGFβ1 ([@B81]) and platelet-derived growth factor (PDGF) ([@B135]; [@B25]) stimulation, among others. To sustain this new highly energetic and extremely expensive "lifestyle," CAF undergo a metabolic reprogramming, thus relying upon aerobic glycolysis, often in a cooperative interaction with tumor cells ([@B46]; [@B83]).

Endowed with the capacity to promote or restrain tumor growth, stromal cells exert their action by manipulating several components of the TME, and in particular immune cells.

MSC Crosstalk With Immune Components of the Inflammatory Niche in Solid Cancer {#S3.SS2}
------------------------------------------------------------------------------

Several studies have underlined the relevance of MSC in supporting tumorigenesis targeting several components and pathways of the TME. Much evidence supports MSCs action on tumor immune cells through their paracrine actions and the ability to modify the microenvironment and consequently the activity of the other cells ([@B137]; [@B120]). MSCs indeed can be induced by cytokines such as IFNγ, tumor necrosis factor alpha (TNFα), and interleukin (IL)-1 to release molecules that are involved in regulation of the innate and adaptive response of the immune system, such as prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO), and chemokines, such as C-X-C chemokine motif ligand (CXCL)-9, CXCL10, and CXLC11, inducible nitric oxide synthase (iNOS) and other catabolites, such as adenosine ([@B112]).

Furthermore, TA-MSCs release mitogens such as epithelial growth factor (EGF), hepatocyte growth factor (HGF), EGF family members, insulin-like growth factor-1 (IGF-1), and different members of the fibroblast growth factor (FGF) family, which are able to directly stimulate cancer cell proliferation, and they release chemokines, such as stromal cell-derived factor-1 (SDF-1/CXCL12) able to trigger the recruitment of progenitor cells or the proliferation of stem cells ([@B48]; [@B110]). As a matter of fact, a role for the stromal compartment in chemo-resistance either through cell--cell contact or in a paracrine fashion has been proposed ([@B20]), and has also been shown to sustain cancer stemness ([@B129]).

Moreover, TA-MSCs can promote EMT favoring tumor spread and the extracellular matrix remodeling ([@B54]). Increased invasiveness has been reported in 3D *in vitro* models based on heterotypic cell culture systems where TA-MSCs modulate ECM stiffness via matrix synthesis and remodeling, thus supporting tumor cell mobility and invasion ([@B1]; [@B28]; [@B76]).

A pro-metastatic phenotype for TA-MSCs has been reported to be dependent on a variety factors, such as CXCL12, shown to favor EMT in prostate cancer ([@B64]) and, together with IGF-1, to select for clones with bone-metastatic ability in breast cancer ([@B145]). In addition, a tumor--MSC--tumor feedback loop involving CCL5 signaling ([@B68]) and enhanced collagen deposition via discoidin domain receptor (DDR)-2 on TA-MSCs ([@B56]) has been shown to stimulate breast cancer motility, invasion, and fibronectin alignment ([@B44]); enhance TA-MSC engulfment by breast cancer cells linked to enhanced metastatic potential ([@B24]); and enhance TA-MSC-derived exosomes by cancer stem cell thus boosting glioma aggressiveness ([@B47]). Exosomes, the smallest (30--150 nm) member of the extracellular vesicle family, represent a carrier for miRNA and other paracrine signals or factors capable of modulating the response of cancer cells and the immune system in the TME ([@B47]; [@B12]).

The following sections of this review will focus on the ability of MSCs to affect tumorigenesis through their interplay and modulation of immune cells within the TME.

### MSCs and Cells of the Innate Immune System {#S3.SS2.SSS1}

MSCs in the TME play a relevant role in favoring the recruitment and differentiation of different subsets of innate immune cells. *In vitro* and *in vivo* studies have shown that MSCs isolated from different sources are able to affect monocyte differentiation toward antigen-presenting cells, skewing them from the canonical inflammatory phenotype to acquire features typical of tolerogenic cells ([@B127]; [@B85]; [@B27]). Furthermore, MSCs skew the differentiation of monocyte-derived dendritic cells toward MDSCs through the action of the secreted growth-regulated oncogene (GRO-y) chemokine ([@B23]). Moreover, MSCs can also trigger the expansion of MDSCs through the release of high amounts of HGFs, demonstrating that the mechanism of function of the MSCs was not strictly associated to the release of immunomodulatory cytokines or chemokines, but was also related to the release of mitogens.

Others have highlighted the relevant role that cancer cells have in educating the stromal component associated to the tumor (TA-MSCs or CAFs), consequently influencing their properties. For example, lymphoma-associated MSCs can trigger the recruitment of neutrophils, monocytes, and macrophages to the TME through the release of high amounts of chemokine (C-C motif) ligand-2 (CCL2), CCL7, and CCL12, all of which are ligands of the CCR2 receptor that mediates chemotaxis and migration processes. The same effect was not observed when the experiments were performed using "non-tumor educated" bone marrow MSCs ([@B113]). The increased expression of the CCR2 ligand on BM-MSC was reported to be strictly related to the exposure to the inflammatory cytokine TNFα ([@B113]). In line with these observations, "tumor-educated" MSCs, and more specifically MSCs isolated from squamous cell lung carcinoma, became more strongly immunosuppressive in comparison to MSCs isolated from healthy tissues. Indeed, TA-MSCs were able to not only affect the phenotype but also decrease the cytotoxic activity of NK cells dampening their immune function ([@B51]). The immunosuppressive mechanisms, as illustrated by the type and quantity of immunosuppressive cytokines produced and the level of NK cell receptor ligands expressed, may differ between healthy and TA-MSCs, possibly as a function of the type of stimulatory microenvironment to which the cells are exposed ([@B51]). In addition, human and mouse TA-MSC exosomes were shown to accelerate breast cancer progression by inducing differentiation of MDSC into highly immunosuppressive M2-polarized macrophages ([@B12]).

In quiescent tissues and in the absence of inflammatory stimuli, MSCs decrease or even temporarily lose their immunosuppressive features. Instead, in a TME that mimics tissue repair and contains a vast array of inflammatory cytokines derived from tumor cells, MSCs can be stimulated to release immunosuppressive molecules.

### MSCs and Cells of the Adaptive Immune System {#S3.SS2.SSS2}

Adaptive immunity plays a fundamental role in controlling tumor progression. After tumor-associated macrophages, T and B lymphocytes are the second most frequent type of immune cell found within the tumor ([@B128]; [@B39]).

In fact, during tumor progression, the loss of immunogenicity by the tumor cells, together with the induction of peripheral tolerance, causes the tumor to evade the action of the cytotoxic component of the immune system ([@B100]).

The mechanism of induction of a peripheral tolerance is considered to be part of the normal control mechanisms of the inflammatory response; MSCs and the tumor stroma play a pivotal role in this regard. For example, bone marrow stromal cells have been shown to skew T lymphocyte toward Treg ([@B102]). Treg induction has been shown to occur through the release of TGFβ1, ultimately protecting breast cancer cells from an immune attack. Indeed, *in vitro* experiments confirmed the capacity of MSCs to affect the TME, creating an immune suppressive microenvironment, whereby BM-MSCs were able to protect T47D breast cancer cells from the cytotoxic activity of CD8 and NK cells by inducing Treg polarization ([@B103]).

In addition, BM-MSCs have been shown to reduce the expression of the chemokine CXCL12 by reducing the recruitment of peripheral blood mononuclear cells (PBMCs) to the tumor and by promoting the polarization of lymphocytes toward a Th2 subset with expansion of Treg cells ([@B103]). The suppressive effect of MSCs was demonstrated also in a murine melanoma model where subcutaneous injection of B16 melanoma cells with MSCs led to tumor growth in allogeneic mice. This effect was related to the capacity of MSCs to inhibit melanoma rejection, putatively through the induction of regulatory CD8^+^ T cells ([@B37]).

On the other hand, the mesenchymal component was shown to inhibit the cytotoxic activity of CD8 lymphocytes in co-culture with BM-MSC by downregulation of HLA-I expressed by CaSki cervical carcinoma cells and downregulation of IL-10 expression ([@B95]). Interestingly, the elimination of CAFs using a FAP-targeting DNA vaccine in the 4T1 murine model of metastatic breast cancer switched the immune microenvironment of the tumor from a Th2 (anti-inflammatory) to a Th1 (pro-inflammatory) phenotype, indicating a key role for CAFs in polarizing the immune response to a pro-tumor type ([@B79]). Similar results were also obtained in a mouse model of breast cancer in which transplanted human MSCs significantly reduced CD3^+^ NKp46 NKT-like cells, increased CD4^+^ Foxp3 T cells and IL-10 expressing CD4^+^ cells, increased serum Th2 cytokines, and decreased serum Th1 cytokines ([@B80]). These results demonstrate that MSCs promote an immunosuppressive environment that ultimately favors breast tumor growth and metastasis in mice.

These studies provide evidence that MSC- and CAF-mediated suppression of adaptive immune cells enhance tumor growth.

### MSC Crosstalk With Immune Cells Depends on Tumor Inflammatory Environment {#S3.SS2.SSS3}

Despite what has been highlighted so far about the role played by MSCs in the TME, MSCs can also exert an immunostimulatory effect triggering the immune response when the inflammatory conditions are suboptimal. An *in vitro* study demonstrated the capacity of antigen pulsed MSCs primed with low levels of IFN-γ to trigger the cytotoxic activity of CD8 T lymphocytes ([@B21]). Similarly, mouse BM-MSCs with reduced or genetically ablated iNOS production, treated with low concentrations of IFNγ and TNF, were found to enhance the proliferation of activated T cells ([@B78]). Similar results were obtained also by another study showing that the development of B16 murine melanoma was accelerated when the melanoma cells were co-injected with MSCs pre-incubated with IFN-γ and TNF-α compared with controls. This effect was reverted when B16 cells were co-injected with iNOS-silenced MSCs ([@B58]).

Importantly, iNOS^--/--^ MSCs significantly inhibited melanoma growth only in wild type, and not in immunodeficient mice, strongly suggesting the involvement of immune cells in the MSC-mediated anti-tumor effect ([@B78]). The observed effects were related to the reduction of IDO and iNOS released by the primed MSCs ([@B78]).

In addition, MSCs can respond to stimuli from the microenvironment by polarizing and acquiring peculiar properties. Initially, two different MSC phenotypes were identified: the proinflammatory MSC1 phenotype originated in response to the toll like receptor 4 (TLR4) priming and the anti-inflammatory MSC2 phenotype derived from the TLR3 priming ([@B103]). Nowadays, this vision is constantly evolving considering MSC plasticity and their ability to serve as "rheostat" cells capable of responding to the environmental stimulus by modifying the factors released. Indeed, low-dose and short-term TLR4 priming of MSCs provides the pro-inflammatory signature, characterized by a higher IL-6 and IL-8 secretion compared to the unstimulated MSC ([@B114]), and the TLR4-primed MSCs were unable to inhibit the proliferation of PBMCs ([@B138]). This therapeutic approach, although fascinating and promising, requires further investigation.

Perinatal MSC as Therapeutic Strategy in Cancer {#S4}
===============================================

In this section, we focus our attention on perinatal MSCs as exogenous MSCs that could be applied in anti-cancer therapy. Perinatal MSCs can be isolated from different placental regions, such as amniotic membrane (hAMSC), umbilical cord/Wharton's jelly (UC-MSC/WJ-MSC), chorionic villi (CV-MSC), and maternal decidua (DMSC) ([@B121]).

The benefits of using perinatal tissue include both technical and biological features, making this material a more valuable choice when compared to others. Technically, perinatal tissues present advantages in terms of tissue accessibility and MSC abundance with respect to adipose tissue and bone marrow. Normally considered medical waste, perinatal tissues (e.g., placenta) can be collected after normal delivery by non-invasive procedures.

Among the unique biological features that make perinatal MSCs valuable as anti-tumor therapeutic approach is their tumor tropism. For example, human amniotic fluid MSCs were shown able to migrate *in vivo* toward ovarian cancer ([@B26]) and bladder cancer, rat UC-MSCs were shown to home to mammary adenocarcinoma ([@B52]) and Lewis lung carcinoma ([@B91]), and human UC-MSCs were detected within or in close proximity to breast tumors in mice ([@B7]).

In addition, perinatal MSCs possess widely recognized intrinsic immune-regulatory properties and indeed they suppress T and B lymphocyte proliferation; inhibit the inflammatory cytokine production and functions of antigen-presenting cells (monocytes, dendritic cells, and macrophages), neutrophils, and NK cells; and enhance the formation of cells with regulatory activity such as Treg and M2 macrophages. Mainly due to these immunomodulatory properties, perinatal MSCs have been successfully exploited in the pre-clinical treatment of inflammatory and immune-based disorders and have been investigated in several clinical trials, such as in peripheral arterial disease and Crohn's disease^[1](#footnote1){ref-type="fn"}^.

On the other hand, similarly to BM-MSCs for which some immunogenic and immune-stimulatory activity has also been described ([@B87]), low concentrations of both fetal (hAMSC, UC-MSC) and maternal (decidual) placental MSCs have been shown to stimulate the proliferation of PBMCs ([@B139]; [@B67]; [@B78]; [@B101]). Therefore, in diseases such as cancer, where the stimulation of immune system has been proposed as an efficient therapeutic strategy ([@B62]), understanding the mechanisms that underline the immune stimulation of perinatal MSCs is fundamental in order to exploit these properties for an anti-cancer therapy. Another important factor that requires investigation is the safety concern regarding the potential tumorigenicity of MSCs. Several studies have shown that placental MSCs do not form tumors when injected either subcutaneously or intravenously in mice ([@B108]; [@B136]). In addition, MSCs from the amniotic membrane ([@B16]) and other tissues ([@B105]; [@B15]) do not proliferate when loaded with the chemotherapeutic drug paclitaxel, which is relevant to suggest their lack of tumorigenesis and potentially safe application. Moreover, the identity of the bioactive factors that contribute to the anti- and pro-tumor actions (those produced by the MSC themselves or induced as bystander effects in the TME) remains another important aspect to be determined before clinical use of perinatal MSCs can be foreseen in the oncology field.

The rationale for the application of perinatal MSCs as anti-tumor therapy relies on features such as (a) their ability to home to tumor sites, (b) their anti-proliferative action on various tumor cell lines *in vitro*, and (c) their ability to shape the inflammatory niche through their intrinsic immune regulatory or stimulatory abilities ([Figure 2](#F2){ref-type="fig"}).

![Perinatal MSCs and their anti-tumor actions. Despite controversial results obtained in investigating the action and the role of MSC in the TME, perinatal MSCs have been reported to exert antitumor actions. More specifically, once perinatal MSCs are injected in a cancer patient, they could home to the tumor and inflammatory site and re-educate the tumor microenvironment through three different actions: **(A)** induction of apoptosis of cancer cells, **(B)** inhibition of cancer cell proliferation, and **(C)** fostering the recruitment of CD4, CD8, and NK cells in the tumor mass, thus activating an anti-tumor response. TA-MSC, tumor associated mesenchymal stromal cell; Treg, T regulatory cell; TAM, tumor associated macrophage; MDSC, myeloid-derived suppressor cell; NK, natural killer cell.](fcell-08-00447-g002){#F2}

Perinatal MSCs have been reported to perform both tumor-supportive and tumor-restraining actions; however, whether this contrasting outcome delineates the versatile immune regulatory ability of MSCs has not been clarified yet.

To date, several *in vitro* and *in vivo* studies have highlighted the anti-tumor potential of perinatal MSCs and of their derivatives, such as conditioned medium (CM) generated from *in vitro* cell culture and extracellular vesicles (EVs) obtained from CM ([@B122]).

UC-MSC/WJ-MSCs represent the most exploited perinatal MSCs in cancer. Many studies evaluated the effects of UC-MSCs, and their secreted factors, on breast cancer cells such as MDA-MB-231 and MCF-7, but with contrasting results. For example, UC-MSCs ([@B7]; [@B52]; [@B22]; [@B84]) and their CM ([@B7]; [@B52]; [@B53]) have been shown to inhibit the *in vitro* proliferation of breast cancer cells such as MDA-MB-231 and MCF-7, while others reported that CM ([@B77]) and EV from UC-MSCs ([@B148]) promote the proliferation and migration of the same cells.

The anti-tumor actions of UC-MSC/WJ-MSCs have also been explored on cancer cell lines other than breast carcinoma. They have indeed been shown to exert *in vitro* anti-proliferative action on ovarian carcinomas ([@B53]; [@B70]) and osteosarcoma (MG-63) ([@B53]). CM from UC-MSC/WJ-MSCs was found to be effective in inhibiting the growth of human glioma (U251) ([@B141]) and leukemia (K562) ([@B59]), and micro-vesicles from UC-MSC/WJ-MSC were reported to attenuate the proliferation of bladder tumor cells (T24) ([@B140]). Controversial actions have been reported for lung carcinoma; indeed, rat UC-MSCs reduced the growth of Lewis lung carcinoma ([@B91]); however, CM from human WJ-MSCs did not affect the proliferation of both A549 lung cancer cells ([@B59]) and SPC-A-1 lung adenocarcinoma cells ([@B93]). In addition, EVs from human UC-MSCs increased proliferation and decreased apoptosis in lung adenocarcinoma cells ([@B40]) and those from human WJ-MSCs fostered the aggressiveness human renal cell carcinoma (786-0) cells ([@B41]).

Pre-clinical tumor models have also been employed to assess the effect of perinatal MSCs on tumor growth and progression. Consistently with *in vitro* results, UC-MSC/WJ-MSCs and their derivatives were able to reduce tumor volume ([@B52]; [@B91]; [@B22]; [@B84]; [@B140]) and counteract lung metastatic growth of breast cancer lines ([@B7]; [@B52]; [@B22]). Interestingly, [@B140] observed that hWJ-MSC-derived micro-vesicles mixed with T24 tumor cells were more effective than hWJ-MSCs *per se* at reducing tumor volume and tumor incidence in a xenograft model of bladder cancer.

In agreement with the pro-tumor activity observed *in vitro*, UC-MSC/WJ-MSCs and derivatives did not reduce tumor volume ([@B93]) and even promoted the growth of lung adenocarcinoma ([@B40]) and of renal cell carcinoma ([@B41]).

Controversial findings were also reported when perinatal cells different from UC-MSC/WJ-MSCs were used as anti-tumor therapy. For example, our group has demonstrated that MSCs derived from amniotic membrane (hAMSCs) inhibited the proliferation *in vitro* of various tumor cell lines, such as hematopoietic \[lymphoid (KG1a, Jurkat), myeloid (KG1, U937)\] and non-hematopoietic Girardi heart, Hela, and Saos tumor cells, both in contact and when cultured in a transwell system, indicating the involvement of secreted factors ([@B86]). In line with our *in vitro* observations, others have shown that intra-tumor injection of hAMSCs inhibited growth and induced apoptosis of C6 glioma ([@B63]). To the contrary, CM from hAMSCs was shown to promote the proliferation and migration of breast cell lines ([@B72]), lung adenocarcinoma cells (SPC-A-1), and gastric carcinoma cells (BGC-823) ([@B93]). Interestingly, the authors of this last study only partially confirmed their findings *in vivo* as hAMSCs were able to stimulate tumor growth when subcutaneously co-injected with SPC-A-1 or BGC-823 tumor cells, but not when injected intravenously 12 days after tumor cell injection when the tumor is well-established ([@B93]). Others instead observed no effects on tumor volume or mice survival when human amniotic fluid MSCs were iv-injected in bladder tumor-bearing animals ([@B13]).

Both CV-MSCs and DMSCs have been shown to possess anti-tumor properties. Indeed, CV-MSCs were shown to inhibit the proliferation and migration of a triple-negative breast cancer cell line (MDA-MB231) *in vitro* ([@B3]), and DMSCs reduced the growth of rat primary mammary tumors induced by N-nitroso-N-methylurea and the development of secondary tumors ([@B134]).

The snapshot of pre-clinical trials outlined here underlines the high degree of plasticity that endows MSCs from perinatal tissues. Indeed, in some of the cases reported above, despite the application of similar experimental conditions (e.g., the same type of perinatal MSC, the same type of target tumor, etc.), MSCs display both anti-tumor and pro-tumor activities, but at present, with current knowledge, it is difficult to say which activity prevails. Nevertheless, there are many technical and biological aspects to be considered when comparing independent studies, such as differences in isolation/culture protocols, presence of xenogenic, possibly immunogenic, factors (such as BSA), in culture media and in the experimental methods of both primary cells and commercial cell lines, as well as variation in oncogenic and mutational pattern, and in the expression of specific receptors by cancer cell lines. In addition, different ratios of MSCs--tumor cells ([@B121]) and timing of MSC delivery into tumors ([@B73]) constitute an important argument in the comparison of different studies. Hence, all these details play a major role in defining MSC properties and impact the final outcome.

Given the pleiotropic nature of perinatal MSCs, different mechanisms have been suggested as mediators of the cells' effect on tumor development. The main mechanism proposed is represented by direct impairment of tumor growth. This process involves tumor cell cycle arrest, accompanied by a decrease in the expression of cyclin A and cyclin-dependent kinase-2 (CDK2) ([@B91]; [@B84]; [@B86]; [@B140]), and/or promotion of tumor cell apoptosis, with upregulation of apoptotic genes (caspase-3 and caspase-9), and downregulation of anti-apoptotic genes \[survivin and X-linked inhibitor of apoptosis protein (XIAP)\] ([@B140]). Perinatal MSCs can attenuate/inhibit the PI3K/AKT pathway, an important regulator of cellular metabolism and the survival and proliferation of tumor cells ([@B7]; [@B52]; [@B84]; [@B140]). An interesting study by [@B22] reported that hUC-MSCs exert their anti-tumor action either by secreting bioactive factors or by becoming internalized by tumor cells to form a cell-in-cell structure resulting in tumor cell apoptosis. To our knowledge, very few papers investigated whether perinatal MSCs can affect the inflammatory environment generated by tumor cells.

This is in part due to the use of tumor-induced animal models where human tumor cells (or tissues) are transplanted in immune deficient mice \[athymic (nude) mice or severe combined immunodeficiency (SCID)\]. These mice lack a normal immune response in order to allow for tumor growth and avoid tumor rejection. However, these conditions do not allow for a complete understanding of the interactions between tumor and immune cells, and the contribution of immune cells in response to therapy with perinatal MSC.

To this regard, one study analyzed the impact of perinatal MSCs on cytokines, growth factors, and chemokines secreted by tumor cells. In this study, supernatants collected from the co-culture of MSCs (hUC-MSCs or hAMSCs) and SPC-A1 lung adenocarcinoma cells revealed that inflammatory factors \[granulocyte stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), intracellular adhesion molecule (ICAM)-1, IL-1a, IL-1b, IL-1ra, IL-8, tissue inhibitor of metalloproteinases (TIMP)-2, IL-10, IL-16, and IL-6sR\], growth factors \[bone morphogenetic protein (BMP)4, platelet-derived growth factor (PDGF)-AA, PDGFBB, vascular endothelial growth factor (VEGF), EGFR, insulin like growth factor binding protein (IGFBP)2, IGFBP3 and bFGF\], and chemokines \[CXCL6, CXCL16, IL-9, IL-18 BPa, leukemia inhibitory factor (LIF), Lymphotactin, macrophage-derived chemokine (MDC), macrophage migration inhibitory factor (MIF), macrophage inflammatory protein (MIP)-3a, growth related oncogene (GRO) and SDF-1a\] were remarkably altered after co-culturing, suggesting that these factors were involved in the regulation of MSC activities on SPC-A-1 cells. Among the downregulated cytokines, the reduction of VEGF, PDGF, and IL-6sR was correlated with anti-migration and anti-angiogenic actions exerted by perinatal MSCs on tumor cells ([@B93]). Another study demonstrated that intra-tumor injection of rat UC-MSCs significantly attenuated tumor growth and concomitantly increased intra-tumor infiltration of CD4^+^ and CD8^+^ T cells and NK cells and decreased levels of intra-tumor macrophages and Treg cells ([@B69]). These findings suggested that rat UC-MSCs can exert anti-tumor action by enhancing host tumor immune responses via promoting MCP-1-mediated recruitment of cytotoxic immune cells in tumor tissues.

Conclusion {#S5}
==========

The TME has a decisive role in tumor progression and more specifically immune cells within the TME have the power to either promote or inhibit tumor growth.

In regenerative medicine, MSCs have long been investigated as a therapeutic strategy, and their contribution to improved outcome has largely been attributed to their unique ability to modulate immune cells. Thus, it comes natural to believe that MSCs, whether local, recruited, or exogenously administered, could re-educate immune cells within the TME. The question is what determines their ability to either favor immunosurveillance and thus inhibit tumor growth, or favor immune editing and thus support tumor growth. This dual role remains an intense area of investigation and is confounded by the plasticity of MSCs and their ability to be molded by the TME milieu.

When considering exogenous MSCs as an anti-cancer strategy, perinatal MSCs have unique features. Perinatal MSCs are largely obtained from the placenta, and the placenta's contribution to the development and growth of a semi-allogeneic fetus during pregnancy favors the idea that cells from the placenta possess intrinsic, peculiar immunological characteristics. Furthermore, the lack of ethical concerns, the easy isolation and handling, and the low/absent expression of human leukocyte antigens and co-stimulatory molecules make perinatal MSCs interesting candidates, especially for allogeneic transplantation. However, their contribution in cancer field and specifically their ability to interact and modulate the immune system of the TME need more investigation since they are no exception to dual roles that MSCs have in tumor progression. Finally, there is also a need to develop immune-competent models in order to better understand the interactions between MSCs and immune cells in the TME.
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